Childhood Cancer Research

You are here

Home » Where the Money Goes » ALSF Funded Projects » Children’s Hospital of Philadelphia

Children’s Hospital of Philadelphia

3401 Civic Center Boulevard
Philadelphia, PA 19104
United States

Patient Centered Outcomes Research Institute (PCORI) Study: Home or Away from Home

Acute Lymphoblastic Leukemia (ALL)

Background

Epigenomic Mechanisms of Neuroblastoma Tumorigenesis

Neuroblastoma

Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma

Neuroblastoma

Background

DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma

Neuroblastoma

Background

Sepsis as innate immune stimulus: severe sepsis exposures and protection against relapse in children with acute leukemias

Leukemia

Background

Children who continue to have small amounts of leukemia after chemotherapy, known as minimal residual disease (MRD), have a high risk of relapse. Since these MRD cells survived through chemotherapy, giving additional standard chemotherapy is not effective and new treatments are urgently needed.

Variation in Care and Outcomes in Pediatric Acute Leukemia - Amanda DiNofia, MD (2016)

Acute Lymphoblastic Leukemia (ALL)

Background

GPC2 as an Oncogene and Immunotherapeutic Target in High-risk Neuroblastoma

Neuroblastoma

Background

CD19 Delta Ex2 Isoform as a Target for Alternative Therapies in Relapsed Pediatric B-ALL

Acute Lymphoblastic Leukemia (ALL)

Background

Mechanisms of Resistance to the TRK-ALK-ROS1 Inhibitor Entrectinib in Neuroblastoma

Neuroblastoma

Backgroud

Genomic Studies in Pediatric AML

Acute Myeloid Leukemia (AML)

Background

Pediatric acute myeloid leukemia (AML) is the second most common pediatric leukemia. While anthracycline intensification has improved survival, it has also increased the risk for cardiac dysfunction. Currently, Dr. Aplenc's laboratory is working to describe the clinical epidemiology and genetic risk factors for early onset cardiac toxicity using data from Children's Oncology Group clinical trials. While anthracycline and other intensive therapies have been somewhat successful, still only 60% of children with AML will be cured.

Pages